A pH-sensitive form of liposomal cisplatin could mean better treatment of peritoneal carcinomatosis (where cancers metastasize throughout the lining of the abdomen), with fewer side effects. The liposomes have been designed by Brazilian researchers to release the drug near the tumor, and tests in mice showed better effects against the cancer, with longer survival, as well as fewer side effects on the kidney and bone marrow. Further studies are under way. The results were published in Experimental Biology and Medicine. Press release | Abstract